Inhibition of natural killer cytotoxicity in vitro by clinical grade serine protease inhibitors

Haematologia

Volumn 32, Issue 2, 2002, Pages 103-111

  Yamamoto, Mitsuteru ^a   Saigo, Katsuyasu ^a   Koshiba, Masahiro ^b   Kitamura, Noriko ^b   Horie, Osamu ^b   Ryo, Ryukichi ^b   Kumagai, Shunichi ^a,b  

^a KOBE UNIVERSITY HOSPITAL   (Japan)

^b KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Calcein AM; Nafamostat mesilate; Natural killer; Serine protease inhibitor; Ulinastatin

Indexed keywords

ANTITHROMBIN III; CALCEIN; CALCIUM CHELATING AGENT; GABEXATE MESILATE; IMMUNOSUPPRESSIVE AGENT; LYMPHOKINE; NAFAMSTAT MESILATE; SERINE PROTEINASE INHIBITOR; ULINASTATIN;

ANALYTIC METHOD; ARTICLE; CELL ACTIVITY; CELL ASSAY; CELL STRAIN K 562; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOKINE ACTIVATED KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; RAJI CELL;

ANTI-BACTERIAL AGENTS; ANTITHROMBIN III; CALCIUM; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; FLUORESCEINS; GABEXATE; GLYCOPROTEINS; GUANIDINES; HUMANS; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; MACROLIDES; SERINE PROTEINASE INHIBITORS; TUMOR CELLS, CULTURED;

EID: 0036905808     PISSN: 00176559     EISSN: None     Source Type: Journal    
DOI: 10.1163/156855902320387934     Document Type: Article

References (25)

1. Brogan, M., Targan, S., Evidence for involvement of serine proteases in the late stages of the natural killer cell lytic reaction, Cell. Immunol. 103, 426-433 (1986).
2. Hudig, D., Allison, N. J., Pickett, T. M., Winkler, U., Kam, C., Powers, J. C., The function of lymphocyte proteases: inhibition and restoration of granule-mediated lysis with isocoumarin serine protease inhibitors, J. Immunol. 147, 1360-1368 (1991).
3. Poe, M., Wu, J. K., Blake, J. T., Zweerink, H. J., Sigal, N. H., The enzymatic activity of human cytotoxic T-lymphocyte granzyme A and cytolysis mediated by cytotoxic T-lymphocytes are potently inhibited by synthetic antiprotease, FUT-175, Arch. Biochem. Biophys. 284, 215-218 (1991).
4. Woodard, S. L., Jackson, D. S., Abuelyaman, A. S., Powers, J. C., Winkler, U., Hudig, D., Chymase-directed serine protease inhibitor that reacts with a single 30-kDa granzyme and blocks NK-mediated cytotoxity, J. Immunol. 153, 5016-5025 (1994).
5. Nishimura, M., Akaza, T., Tadokoro, K., Juji, T., Potential usefulness of protease inhibitor and chloroquine in the treatment of transfusion associated graft-versus-host disease, Transfusion 37, 768-770 (1997).
6. Ewoldt, G. R., Winkler, U., Powers, J. C., Hudig, D., Sulfonyl fluoride serine protease inhibitors inactivate RNK-16 lymphocyte granule proteases and reduce lysis by granule extracts and perforin, Mol. Immunol. 29, 713-725 (1992).
7. Ryo, R., Saigo, K., Hashimoto, M., Kohsaki, M., Yasufuku, M., Watanabe, N., Okada, M., Tadokoro, K., Juji, T., Treatment of post-transfusion graft-versus-host disease with nafamostat mesilate, a serine protease inhibitor, Vox. Sang. 76, 241-246 (1999).
8. Zhang, J. L., Yamaguchi, Y., Mori, K., Okabe, K., Hidak, H., Ohshiro, H., Uchino, S., Ishihara, K., Furuhashi, T., Yamada, S., Ogawa, M., A serine protease inhibitor, N-α-tosyl-L-lysine-chloromethyl ketone, prolongs rat hepatic allograft survival, J. Surg. Res. 96, 296-303 (2001).
9. Kagan, E., Hartmann, D. P., Elimination of macrophages with silica and asbestos, Methods Enzymol. 108, 325-335 (1984).
10. Ryo, R., Yasunaga, M., Saigo, K., Yamaguchi, N., Megakaryocytic leukemia and platelet factor 4, Leuk. Lymphoma 8, 327-336 (1992).
11. Wang, X. M., Terasaki, P. I., Rankin, G. W., Chia, D., Zhang, H. P., Hardy, S., A new microcellular cytotoxicity test based on calcein AM release, Human Immunol. 37, 264-270 (1993).
12. Lichtenfels, R., Biddison, W. E., Schulz, H., Vogt, A. B., Martin, R., Care-Lass (Calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity, J. Immunol. Methods 172, 227-239 (1994).
13. Kataoka, T., Shinohara, N., Takayama, H., Takaku, K., Kondo, S., Yonehara, S., Nagai, K., Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin-and Fas-based lytic pathways in cell-mediated cytotoxicity, J. Immunol. 156, 3678-3686 (1996).
14. Li, J.-H., Rosen, D., Behrens, C. K., Krammer, P. H., Clark, W. R., Berke, G., The regulation of CD95 ligand expression and function in CTL, J. Immunol. 161, 3943-3949 (1998).
15. Yasukawa, M., Ohminami, H., Yakushijin, Y., Ishida, Y., Fujita, S., Fas-independent cytotoxicity mediated by human CD4(+) CTL directed against herpes simplex virus-infected cells, J. Immunol. 162, 6100-6106 (1999).
16. Yasukawa, M., Ohminami, H., Arai, J., Kasahara, Y., Ishida, Y., Fujita, S., Granule exocytosis, and not the Fas/Fas ligand system, is the main pathway of cytotoxicity mediated by alloantigen-specific CD4(+) as well as CD8(+) cytotoxic T lymphocytes in humans, Blood 95, 2352-2355 (2000).
17. Stohl, W., Lynch, D. H., Starling, G. C., Kiener, P. A., Super antigen-driven, CD8(+) T cell-mediated down-regulation: CD95 (Fas)-dependent down-regulation of human Ig responses despite CD95-independent killing of activated B cells, J. Immunol. 161, 3292-3298 (1998).
18. 2+ and IL-2 production in activated jurkat T cells, J. Immunol. 142, 1253-1259 (1989).
19. Simon, M. M., Hausmann, M., Tran, T., Ebnet, K., Tschopp, J., Thahla, R., Mullbacher, A., In vitro- and ex vivo-derived cytolytic leukocytes from granzyme A × B double knockout mice are defective in granule-mediated apoptosis but not lysis of target cells, J. Exp. Med. 17, 1781-1786 (1997).
20. Smyth, M. J., Thia, K. Y. T., Cretney, E., Kelly, J. M., Snook, M. B., Forbes, C. A., Scalzo, A. A., Perforin is a major contributor to NK cell control of tumor metastasis, J. Immunol. 162, 6658-6662 (1999).
21. Yanagihara, Y., Shida, T., Immunopharmacological actions of 6-amidino-2-naphthyl-4-guaninobenzoate (FUT-175)(1): Effects of FUT-175 on immune response and host defence in mice. Folia Pharmacol. Japon. 81, 565-572 (1988) (in Japanese with English abstract).
22. Saigo, K., Ryo, R., Therapeutic strategy for post-transfusion graft-vs-host disease, Int. J. Hematol. 69, 147-151 (1999).
23. Inagaki, H., Nonami, T., Kurokawa, T., Takeuchi, Y., Okuda, N., Nakao, A., Sakamoto, J., Effects of nafamostat mesilate, a synthetic protease inhibitor, on immunity and coagulation after hepatic resection, Hepatogastroenterology 46, 3223-3228 (1999).
24. Badovinac, V P., Tvinnereim, A. R., Harty, J. T., Regulation of antigen-specific CD8+ T cell homeostasis by perforin and interferon-gamma, Science 290, 1354-1358 (2000).
25. Bladergroen, B. A., Meijer, C. J., ten Berge, R. L., Hack, C. E., Muris, J. J., Dukers, D. F., Chott, A., Kazama, Y, Oudejans, J. J., van Berkum, O., Kummer, J. A., Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?, Blood 99, 232-237 (2002).